ProAssurance Co. (NYSE:PRA) Shares Sold by Caxton Associates LP

Caxton Associates LP lessened its stake in shares of ProAssurance Co. (NYSE:PRA) by 17.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 17,003 shares of the insurance provider’s stock after selling 3,714 shares during the quarter. Caxton Associates LP’s holdings in ProAssurance were worth $271,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of ProAssurance by 859.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,631 shares of the insurance provider’s stock valued at $26,000 after purchasing an additional 1,461 shares during the last quarter. KBC Group NV lifted its stake in ProAssurance by 75.4% during the fourth quarter. KBC Group NV now owns 4,184 shares of the insurance provider’s stock valued at $67,000 after buying an additional 1,798 shares in the last quarter. Aquatic Capital Management LLC boosted its holdings in shares of ProAssurance by 148.6% in the fourth quarter. Aquatic Capital Management LLC now owns 6,214 shares of the insurance provider’s stock worth $99,000 after buying an additional 3,714 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of ProAssurance in the fourth quarter worth approximately $150,000. Finally, Scotia Capital Inc. acquired a new stake in shares of ProAssurance during the fourth quarter valued at approximately $173,000. 85.58% of the stock is owned by institutional investors.

ProAssurance Price Performance

Shares of NYSE:PRA opened at $22.96 on Thursday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 27.66 and a beta of 0.04. ProAssurance Co. has a 1 year low of $10.76 and a 1 year high of $23.70. The company has a current ratio of 0.28, a quick ratio of 0.28 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $21.18 and a 200 day simple moving average of $17.55.

ProAssurance (NYSE:PRA) last posted its quarterly earnings results on Tuesday, May 6th. The insurance provider reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.06). The firm had revenue of $236.28 million for the quarter, compared to analysts’ expectations of $272.85 million. ProAssurance had a return on equity of 2.65% and a net margin of 3.71%. The firm’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same period last year, the business earned $0.08 earnings per share. As a group, sell-side analysts predict that ProAssurance Co. will post 0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PRA. StockNews.com began coverage on shares of ProAssurance in a research report on Saturday, May 3rd. They set a “hold” rating on the stock. Citizens Jmp downgraded ProAssurance from an “outperform” rating to a “market perform” rating in a report on Thursday, April 3rd. Raymond James downgraded ProAssurance from a “market perform” rating to an “underperform” rating in a research note on Thursday, April 10th. Finally, Citigroup cut ProAssurance to a “market perform” rating in a research note on Thursday, April 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $18.67.

ProAssurance Company Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.